Mathias Haenel

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

Kai Neben, Henk M. Lokhorst, Anna Jauch et al. · Blood · 2011 · 353 citations

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

Norbert Schmitz, Maike Nickelsen, Marita Ziepert et al. · The Lancet Oncology · 2012 · 247 citations

Hematological Malignancy, Lymphoid Neoplasia, Conventional Chemotherapy +8

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Viola Poeschel, Gerhard Held, Marita Ziepert et al. · The Lancet · 2019 · 244 citations · Full text

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

E. K., Uta Bertsch, Jan Dürig et al. · Leukemia · 2015 · 140 citations

Hematological Malignancy, Oncology, Versus Bortezomib +7

Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies

Frank Kroschinsky, Matthias Weise, Thomas Illmer et al. · Intensive Care Medicine · 2002 · 130 citations

Critical Care Management, Critical Care Medicine, Medicine +8